Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 26, 2022, the Board of Directors (the "Board") and the Compensation
Committee (the "Committee") of the Board of Ligand Pharmaceuticals Incorporated
(the "Company") approved cash bonus payments for the 2021 fiscal year to be paid
to the Company's named executive officers. Bonus payments were based on the
Committee's evaluation of performance goals for 2021. Such goals related to the
achievement of certain corporate finance and licensing objectives and the
advancement of the Company's business.
The 2021 bonuses to be paid to each named executive officer are as follows:
Name and title 2021 Bonus
John L. Higgins, Chief Executive Officer $522,438
Matthew W. Foehr, President and Chief Operating Officer $259,467
Matthew Korenberg, Executive Vice President and Chief Financial $248,649
Officer
Charles S. Berkman, Senior Vice President, General Counsel and $203,257
Secretary
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses